Options revision & Grant of new share options

Verici Dx

30/10/2025 07:00

RNS Number : 3805F

Verici Dx PLC

30 October 2025

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Options revision

&

Grant of new share options

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that upon the recommendation of the Company's Remuneration Committee, it has repriced certain existing options over ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") ("Share Options") over an aggregate of 15,577,304 Ordinary Shares and granted new Share Options over an aggregate 107,800,000 Ordinary Shares to certain Directors, persons discharging management responsibility ("PDMRs"), employees and consultants of the Company. The goal of the review was to realign with previous remuneration targets and the issued pool of options including those for new team members now represents 8.32% of the Company's total voting rights as compared with the previous pool of 7.98%.

 

The Company's Remuneration Committee recognises the importance of share options to appropriately incentivise and retain Directors and employees, as well as to ensure their interests are aligned with that of Company and its shareholders. Following a review of incentive plans, the Remuneration Committee of the Board recommended that, given the reduction in the Company's share price and the changes in the share capital following the recent fundraising, the existing awards of share options were no longer a reasonable incentive and should be amended to re-align the option scheme with the current share price and share capital.

 

Accordingly, the Company has agreed with each of Sara Barrington, Chief Executive Officer, David Anderson, Chief Financial Officer and Lorenzo Gallen, Non-Executive Director, that the exercise price in respect of the options granted to Sara Barrington and David Anderson on 28 October 2020 around the time of the Company's IPO, and of those granted to Lorenzo Gallon on 6 December 2022 is amended from 20 pence to 0.525 pence per Ordinary Share. All other terms of these Share Options remain the same. All of the Share Options granted in October 2020 have vested in full and can be exercised at any time until 28 October 2030. The Share Options granted in December 2022 have vested in full and can be exercised at any time until 6 December 2032.  The numbers of Share Options currently held by Directors and PDMR's and being repriced are shown in the following table:

 

Name
Position
Existing Options
Previous Exercise Price (per share)
New Exercise Price (per share)
Sara Barrington
Chief Executive Officer
5,669,913
£0.2
£0.00525
David Anderson
Chief Financial Officer
708,739
£0.2
£0.00525
Lorenzo Gallon
Non-Executive Director
354,370
£0.2
£0.00525

 

Additionally, the Board has granted new options over a total of 107,800,000 Ordinary Shares (the "New Share Options") to certain Directors, PDMRs, employees and consultants of the Company. Of the Company's Directors and PDMRs, this includes:

 

Name
Position
Options granted
Total Options
Resultant total holding as a % of total voting rights
Sara Barrington
Chief Executive Officer
54,900,000
60,569,913
4%
David Anderson
Chief Financial Officer
6,800,000
7,508,739
0.5%
Lorenzo Gallon
Non-Executive Director
1,900,000
2,254,370
0.15%

 

The remaining 44,200,000 New Share Options have been granted to employees of the Company including recent joiners in the sales team, and it is also the intention to grant New Share Options to new employees who are in the process of joining the Company.

 

The New Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of 0.525 pence per ordinary share. This was the price on 2 September 2025 when the Board initially resolved to grant these options but were unable to do so at the time due to the closed period ahead of the Company's interim results. The vesting conditions for the New Share Options granted to the Directors and PDMR's and Chief Operating Officer are 50% performance-based and 50% time-based, with the share option grant initially vesting 12 months from the date of grant. These New Share Options can be exercised until the tenth anniversary from date of grant.

 

The repricing of the Share Options and the issue of the New Share Options are deemed to be related party transactions under AIM Rule 13 of the AIM Rules for Companies. The Company's Directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Singer Capital Markets, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.

 

Following the grant of the New Share Options referred above, there are 125,849,152 outstanding options over Verici's Ordinary Shares, representing 8.32% of the Company's total voting rights. The percentage of outstanding options over Verici's Ordinary Shares prior to this new grant was 7.98%.

 

Verici Dx plc
www.vericidx.com
Sara Barrington, CEO
Via Walbrook PR
Singer Capital Markets (Nominated adviser and Joint Broker)
Tel: +44 (0)20 7496 3000
Phil Davies / Sam Butcher
Oberon Capital (Joint Broker)
Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Paul McManus
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893


 

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
A) Sara Barrington
B) David Anderson
C) Lorenzo Gallon
2
Reason for the notification
a)
Position/status
A) Chief Executive Officer
B) Chief Financial Officer
C) Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Verici Dx plc
b)
LEI
213800FI5WE4FVQ3G645
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Options over ordinary shares of 0.1 pence each in the Company
Identification code
GB00BM8HZD43
b)
Nature of the transaction
Grant of options over shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Exercise price of 0.525 pence per share
A) 54,900,000
B) 6,800,000
C) 1,900,000
d)
Aggregated information
N/A
- Aggregated volume
N/A
- Price
e)
Date of the transaction
30 October 2025
f)
Place of the transaction
Outside of trading venue - off market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHMLBFTMTJTBJA